Yes, you can continue topiramate while initiating lamotrigine for a mood disorder in this MS patient
Based on FDA drug labeling data, there is no clinically significant pharmacokinetic interaction between topiramate and lamotrigine at doses up to 400 mg/day of topiramate, making concurrent use safe from a drug interaction standpoint 1. The MS diagnosis itself does not contraindicate this combination, particularly given the patient's current asymptomatic status and stable disease.
Drug Interaction Profile
The FDA labeling for topiramate explicitly states that lamotrigine concentrations show "NC" (no change, defined as less than 10% change in plasma concentration) at topiramate doses up to 400 mg/day 1. This means:
- Topiramate does not significantly alter lamotrigine levels
- Lamotrigine causes a modest 15% increase in topiramate levels 1
This 15% increase in topiramate concentration is generally not clinically significant and does not require dose adjustment in most patients. However, you should monitor for topiramate-related side effects (paresthesias, cognitive effects, kidney stones) that might become more apparent with this modest increase.
Mood Disorder Treatment Considerations
For mood disorders, particularly bipolar disorder, both medications have evidence supporting their use:
- Lamotrigine is FDA-approved for maintenance therapy in bipolar disorder in adults 2
- Topiramate has case report evidence as a mood stabilizer, though it is not FDA-approved for this indication 3
The combination may actually provide additive mood stabilization benefits, though this is not formally studied. One case report demonstrated successful mood stabilization with topiramate monotherapy in a patient with bipolar I disorder who had failed multiple other agents 3.
MS-Specific Considerations
Neither medication is contraindicated in MS patients. In fact:
- Topiramate has been used successfully to treat MS-related symptoms including cerebellar ataxia, tremor, and dysesthetic pain 4, 5
- Lamotrigine was studied as a potential neuroprotective agent in secondary progressive MS (though it did not show benefit for disease modification) 6
- The 2011 NCCN guidelines for CNS cancers note that newer antiepileptic drugs including both levetiracetam, topiramate, and lamotrigine are non-enzyme-inducing and preferred over older agents 7
Since your patient is asymptomatic with stable MRI findings and not on disease-modifying therapy, there are no MS-related concerns that would preclude this combination.
Practical Implementation Strategy
Start lamotrigine using standard slow titration to minimize rash risk:
- Begin lamotrigine at 25 mg daily for 2 weeks
- Increase to 50 mg daily for 2 weeks
- Then increase by 50 mg every 1-2 weeks to target dose (typically 200-400 mg/day for mood disorders)
- Continue topiramate at current dose without adjustment
Monitor for:
- Rash (lamotrigine's most serious risk - discontinue immediately if rash develops)
- Cognitive effects (both drugs can cause this; the combination may be additive)
- Paresthesias (topiramate effect, may be more noticeable with increased levels)
- Mood symptoms (to assess therapeutic response)
- Kidney stones (topiramate risk - ensure adequate hydration) 1
Important Caveats
Depression monitoring: Both medications require monitoring for mood changes and suicidal ideation 8. The obesity management guidelines note that topiramate (in combination with phentermine) should be used with caution in patients with depression, though this refers to the higher doses used for weight loss 8.
Avoid valproic acid: If you were considering valproic acid instead, note that concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy 1. This is not a concern with lamotrigine.
Carbonic anhydrase inhibitors: Avoid combining topiramate with other carbonic anhydrase inhibitors (acetazolamide, dichlorphenamide) as this increases kidney stone risk 1.